BB Biotech AG Stock price

Equities

BION

CH0038389992

Biotechnology & Medical Research

Market Closed - Swiss Exchange 12:31:47 2024-03-18 pm EDT 5-day change 1st Jan Change
47.65 CHF -0.83% Intraday chart for BB Biotech AG -3.35% +11.46%
Sales 2024 * 32.1M 36.16M Sales 2025 * 100M 113M Capitalization 2.61B 2.94B
Net income 2024 * 25M 28.16M Net income 2025 * 72M 81.1M EV / Sales 2024 * 92.4 x
Net Debt 2024 * 354M 398M Net Debt 2025 * 362M 408M EV / Sales 2025 * 29.7 x
P/E ratio 2024 *
95.3 x
P/E ratio 2025 *
16 x
Employees 10
Yield 2024 *
5.16%
Yield 2025 *
5.16%
Free-Float 97.24%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.83%
1 week-1.45%
Current month+4.04%
1 month-2.85%
3 months+14.27%
6 months+8.91%
Current year+11.46%
More quotes
1 week
46.90
Extreme 46.9
49.50
1 month
45.00
Extreme 45
49.80
Current year
42.30
Extreme 42.3
49.80
1 year
35.35
Extreme 35.35
53.50
3 years
35.35
Extreme 35.35
92.40
5 years
35.35
Extreme 35.35
93.45
10 years
26.42
Extreme 26.42
93.45
More quotes
Managers TitleAgeSince
Chief Investment Officer 54 03-12-31
- -
- -
Members of the board TitleAgeSince
Chairman 70 11-03-20
Director/Board Member 67 03-12-31
Director/Board Member 63 19-12-31
More insiders
Date Price Change Volume
24-03-18 47.65 -0.83% 76,770
24-03-15 48.05 +1.48% 97,673
24-03-14 47.35 -0.73% 77,700
24-03-13 47.7 -2.55% 87,927
24-03-12 48.95 -0.71% 61,785

Delayed Quote Swiss Exchange, March 18, 2024 at 12:31 pm EDT

More quotes
BB Biotech is a portfolio company that specializes in investments in biotechnology companies. At the end of 2018, the stock portfolio, assessed at market value to be EUR3,064.2 million, breaks down by type of holding as follows: - listed companies (99.9%): primarily Ionis Pharmaceuticals (rare diseases), Gilead Sciences (infectious viral diseases and flu), Celgene Corporation (cancer and inflammation of the immune system), Esperion Therapeutics (cardio-metabolic diseases), Vertex Pharmaceuticals (infectious diseases and diseases of the immune system) and Incyte (cancers, hematologic disorders and inflammatory diseases); - other (0.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
47.65 CHF
Average target price
66.36 CHF
Spread / Average Target
+39.27%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock BB Biotech AG - Swiss Exchange